rs10748835
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data promotes the realization that AS3MT 35587 (rs11191453), 35991 (rs10748835), especially their joint genotypes 35991 (rs10748835) AA / 35587 (rs11191453) TC+CC, is a novel predictive biomarker for the therapeutic efficacy of As<sub>2</sub>O<sub>3</sub> in the treatment of APL.
|
31330140 |
2019 |
rs10821936
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found that the association of <i>ARID5B</i> polymorphisms with AML was most significant in acute promyelocytic leukemia (APL), and exclusively in males, the mutant alleles of rs6415872, rs2393726, rs7073837, rs10821936, and rs7089424 were found to increase the risk of developing APL in men, the odds ratio (OR) were 1.36, 1.74, 1.45, 1.53, and 1.56 (all <i>p</i> < 0.05), respectively.
|
31599655 |
2019 |
rs11191453
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data promotes the realization that AS3MT 35587 (rs11191453), 35991 (rs10748835), especially their joint genotypes 35991 (rs10748835) AA / 35587 (rs11191453) TC+CC, is a novel predictive biomarker for the therapeutic efficacy of As<sub>2</sub>O<sub>3</sub> in the treatment of APL.
|
31330140 |
2019 |
rs2393726
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found that the association of <i>ARID5B</i> polymorphisms with AML was most significant in acute promyelocytic leukemia (APL), and exclusively in males, the mutant alleles of rs6415872, rs2393726, rs7073837, rs10821936, and rs7089424 were found to increase the risk of developing APL in men, the odds ratio (OR) were 1.36, 1.74, 1.45, 1.53, and 1.56 (all <i>p</i> < 0.05), respectively.
|
31599655 |
2019 |
rs6415872
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, <i>ARID5B</i> single nucleotide polymorphisms were found associated with clinical features of AML, and rs6415872 was shown to be an independent prognosis factor in APL patients.
|
31599655 |
2019 |
rs7073837
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found that the association of <i>ARID5B</i> polymorphisms with AML was most significant in acute promyelocytic leukemia (APL), and exclusively in males, the mutant alleles of rs6415872, rs2393726, rs7073837, rs10821936, and rs7089424 were found to increase the risk of developing APL in men, the odds ratio (OR) were 1.36, 1.74, 1.45, 1.53, and 1.56 (all <i>p</i> < 0.05), respectively.
|
31599655 |
2019 |
rs7089424
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found that the association of <i>ARID5B</i> polymorphisms with AML was most significant in acute promyelocytic leukemia (APL), and exclusively in males, the mutant alleles of rs6415872, rs2393726, rs7073837, rs10821936, and rs7089424 were found to increase the risk of developing APL in men, the odds ratio (OR) were 1.36, 1.74, 1.45, 1.53, and 1.56 (all <i>p</i> < 0.05), respectively.
|
31599655 |
2019 |
rs11191439
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this article, the associations among urinary arsenic profiles, hematological and biochemical values, and 3 AS3MT genotypes (rs3740392, rs3740390, and rs11191439) were evaluated in 50 APL patients treated with arsenic trioxide (As2O3).
|
30376134 |
2018 |
rs3740390
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These results indicate that inherent genetic information of the AS3MT rs3740390 genotypes is a novel predicted or evaluated target for As2O3-induced side effects and therapeutic efficacy for the treatment of APL.
|
30376134 |
2018 |
rs7560488
|
|
|
0.010 |
GeneticVariation |
BEFREE |
DNMT3A 11 SNPs (rs11695471, rs2289195, rs734693, rs2276598, rs1465825, rs7590760, rs13401241, rs7581217, rs749131, rs41284843 and rs7560488) were genotyped in 344 diagnostic non-FAB-M3 AML patients from southern China.
|
27528035 |
2016 |
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
rs16754
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia.
|
22895555 |
2012 |
rs2234767
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated a common G > A polymorphism at position -1377 (rs2234767) in the core promoter of the CD95 cell death receptor gene in 708 subjects with acute myeloid leukemia, including 231 patients with APL.
|
22084312 |
2012 |
rs397517132
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
rs1057519753
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sequencing of a mouse APL genome revealed 3 somatic, nonsynonymous mutations relevant to APL pathogenesis, of which 1 (Jak1 V657F) was found to be recurrent in other affected mice.
|
21436584 |
2011 |
rs41293463
|
|
|
0.010 |
GeneticVariation |
BEFREE |
M1775R induced unusual, thread-like promyelocytic leukemia (PML) nuclear bodies and clustered RPA foci rather than the typical juxtaposed RPA-PML foci seen with wild-type BRCA1.
|
21666281 |
2011 |
rs121912438
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, using an astroglial cell line, primary culture of astrocytes, and tissue samples from G93A-SOD1 mice, we show that CTE-SUMO-1 is targeted to promyelocytic leukemia nuclear bodies.
|
17823119 |
2007 |
rs1799969
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As leukocyte extravasation is a key event in DS pathogenesis, we analyzed the association between the polymorphisms at Exon 4 (G241R) and Exon 6 (E469K) of ICAM-1 and Exon 3 (L125V) of PECAM-1 genes with DS development in APL patients treated with ATRA and anthracyclines.
|
17704297 |
2007 |
rs281865545
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As leukocyte extravasation is a key event in DS pathogenesis, we analyzed the association between the polymorphisms at Exon 4 (G241R) and Exon 6 (E469K) of ICAM-1 and Exon 3 (L125V) of PECAM-1 genes with DS development in APL patients treated with ATRA and anthracyclines.
|
17704297 |
2007 |
rs5498
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As leukocyte extravasation is a key event in DS pathogenesis, we analyzed the association between the polymorphisms at Exon 4 (G241R) and Exon 6 (E469K) of ICAM-1 and Exon 3 (L125V) of PECAM-1 genes with DS development in APL patients treated with ATRA and anthracyclines.
|
17704297 |
2007 |